

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 1, 2025

Anti-Human CD25 (2A3)-169Tm

RRID:AB_2661806

Type: Antibody

Proper Citation

(Standard BioTools Cat# 3169003, RRID:AB_2661806)

Antibody Information

URL: http://antibodyregistry.org/AB_2661806

Proper Citation: (Standard BioTools Cat# 3169003, RRID:AB_2661806)

Target Antigen: CD25

Clonality: unknown

Antibody Name: Anti-Human CD25 (2A3)-169Tm

Description: This unknown targets CD25

Target Organism: human

Clone ID: 2A3

Antibody ID: AB_2661806

Vendor: Standard BioTools

Catalog Number: 3169003

Alternative Catalog Numbers: 3169003B

Record Creation Time: 20231110T034348+0000

Record Last Update: 20240725T062823+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD25 (2A3)-169Tm.

No alerts have been found for Anti-Human CD25 (2A3)-169Tm.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Gerassy-Vainberg S, et al. (2024) A personalized network framework reveals predictive axis of anti-TNF response across diseases. Cell reports. Medicine, 5(1), 101300.

Rachubinski AL, et al. (2024) JAK inhibition decreases the autoimmune burden in Down syndrome. eLife, 13.

Shinde P, et al. (2024) A multi-omics systems vaccinology resource to develop and test computational models of immunity. Cell reports methods, 4(3), 100731.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer cell, 41(4), 693.

Povoleri GAM, et al. (2023) Psoriatic and rheumatoid arthritis joints differ in the composition of CD8+ tissue-resident memory T cell subsets. Cell reports, 42(5), 112514.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer cell, 41(5), 837.

McCarthy EE, et al. (2022) A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell reports, 39(7), 110815.

Georg P, et al. (2022) Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 185(3), 493.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.

Sullivan KD, et al. (2021) The COVIDome Explorer researcher portal. Cell reports, 36(7), 109527.

Galbraith MD, et al. (2021) Seroconversion stages COVID19 into distinct pathophysiological states. *eLife*, 10.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell*, 182(6), 1419.

Pai CS, et al. (2019) Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. *Immunity*, 50(2), 477.

Waugh KA, et al. (2019) Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. *Cell reports*, 29(7), 1893.

Hartmann FJ, et al. (2019) Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy. *Cell reports*, 28(3), 819.

Azizi E, et al. (2018) Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. *Cell*, 174(5), 1293.

Lavin Y, et al. (2017) Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. *Cell*, 169(4), 750.

Wei SC, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell*, 170(6), 1120.